Magnetically vectored platforms for the targeted delivery of therapeutics to tumors: History and current status

Nanomedicine

Volumn 7, Issue 2, 2012, Pages 289-299

  Seeney, Charles ^a   Ojwang, Joshua O ^a   Weiss, Ronald D ^b   Klostergaard, Jim ^c  

^a NanoBioMagnetics Inc   (United States)

^b Arkival Technology Corporation   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

magnetic vectoring; nanomagnetics; nanomedicine; nanotechnology; silica coated nanoparticles; superparamagnetics; targeted drug delivery

Indexed keywords

DOXORUBICIN; DRUG CARRIER; EPIRUBICIN; MAGNETIC NANOPARTICLE; MAGNETICALLY RESPONSIVE NANOPARTICLE; MAGNETICALLY TARGETED CARRIER; MITOXANTRONE; NANOMATERIAL; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; UNCLASSIFIED DRUG;

CANCER LOCALIZATION; CANCER MODEL; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG TARGETING; HUMAN; IN VIVO STUDY; LIVER CELL CARCINOMA; MAGNETIC FIELD; METHODOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; FORECASTING; HUMANS; MAGNETITE NANOPARTICLES; MOLECULAR TARGETED THERAPY; NANOCAPSULES; NEOPLASMS;

EID: 84857573142     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.11.183     Document Type: Review

References (62)

1. Jain K. Drug delivery systems -an overview. Methods Mol. Biol. 437, 1-50 (2008).
2. Park K. Controlled Drug Delivery: Challenges and Strategies. American Chemical Society, DC, USA (1997).
3. Ferretti T. Tumor interstitial fluid pressure as an early-response marker for anticancer therapeutics. Neoplasia 11, 874-881 (2009).
4. Wilkinson E. Tailoring cancer therapy -validating basic science with the 'supertrial'. Mol. Oncol. 3, 389-391 (2009).
5. Farokhzada O, Langer R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv. Drug Deliv. Rev. 58(14), 1456-1459 (2006).
6. Pankhurst Q, Connolly J, Jones S, Dobson J, Applications of magnetic nanoparticles in biomedicine. J. Phys. D. Appl. Phys. 36, R167-R181 (2003).
7. Dobson J. Magnetic nanoparticles for drug delivery. Drug Devel. Res. 67(1), 55-60 (2006).
8. Dobson J. Magnetic micro-and nano-particle-based targeting for drug and gene delivery. Nanomedicine (Lond.) 1(1), 31-37 (2006).
9. Barakat NS. Magnetically modulated nanosystems: A unique drug-delivery platform. Nanomedicine 4(7), 799-812 (2009).
10. Rotariu O, Strachan NJC. Modelling magnetic carrier particle targeting in the tumor microvasculature for cancer treatment. J. Magn. Magn. Mater. 293(1), 639-646 (2005).
11. Hayden ME, Häfeli UO. Magnetic bandages for targeted delivery of therapeutic agents. J. Phys. Condens. Matter 18, S2877-S2891 (2006).
12. Widder K, Senyei A, Scarpelli D. Magnetic microspheres: A model system for site-specific drug delivery. Proc. Soc. Exp. Biol. Med. 58, 141-146 (1978).
13. Widder KJ, Morris RM, Poore G, Howard DP Jr, Senyei AE. Tumor remission in Yoshida sarcoma-bearing rats by selective targeting of magnetic albumin microspheres containing doxorubicin. Proc. Natl Acad. Sci. USA 78(1), 579-581 (1981).
14. Jurgons R, Seliger C, Hilpert A, Trahms L, Odenbach S, Alexiou C. Drug loaded magnetic nanoparticles for cancer therapy. J. Phys. Condens. Matter 18, S2893-S2902 (2006).
15. Lubbe A, Bergemann C, Brock J, McClure D. Physiological aspects in magnetic drug targeting. J. Magn. Magn. Mater. 194, 149 (1999).
16. Alexiou C, Arnold W, Klein R, et al. Locoregional cancer treatment with magnetic drug targeting. Cancer Res. 60(23), 6641-6648 (2000).
17. Goodwin S, Peterson C, Hoh C, Bittner C. Targeting and retention of magnetic targeted carriers (MTCs) enhancing intra-arterial chemotherapy. J. Mag. Mag. Mater. 132, 194 (1999).
18. Goodwin SC, Bittner CA, Peterson CL, Wong G. Single-dose toxicity study of hepatic intra-arterial infusion of doxorubicin coupled to a novel magnetically targeted drug carrier. Toxicol. Sci. 60, 177 (2001).
19. Koda J, Venook A, Walser E. A multicenter, Phase I/II trial of hepatic intraarterial delivery of doxorubicin hydrochloride adsorbed to magnetic targeted carriers in patients with hepatocellular carcinoma. Eur. J. Cancer 38, 518 (2002).
20. Wilson, MW, Kerlan RK, Fidelman NA, et al. Hepatocellular carcinoma: regional therapy with a magnetic targeted carrier bound to doxorubicin in a dual MR imaging/ conventional angiography suite -initial experience with four patients. Radiology 230, 287-293 (2004).
21. Prijic S, Sersa G. Magnetic nanoparticles as targeted delivery systems in oncology. Radiol. Oncol. 45(1), 1-16 (2011).
22. Leakakos T, Ji C, Lawson G, Peterson C, Goodwin S. Intravesical administration of doxorubicin to swine bladder using magnetically targeted carriers. Cancer Chemother. Pharmacol. 51(6), 445-450 (2003).
23. Lübbe AS, Bergemann C, Huhnt W, et al. Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res. 56(20), 4694-4701 (1996).
24. Lübbe AS, Bergemann C, Riess H, et al. Clinical experiences with magnetic drug targeting: A Phase I study with 4́-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res. 56(20), 4686-4693 (1996).
25. Matsuo M, Kanematsu M, Itoh K, et al. MR imaging of malignant hepatic tumors. Am. J. Radiol. 177, 637-643 (2001).
26. Alexiou C, Arnold W, Klein RJ, et al. Locoregional cancer treatment with magnetic drug targeting. Cancer Res. 60(23), 6641-6648 (2000).
27. Lübbe AS, Alexiou C, Bergemann C. Clinical applications of magnetic drug targeting. J. Surg. Res. 95(2), 200-206 (2001).
28. Alexiou C, Jurgons R, Schmid RJ, et al. Magnetic drug targeting -biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment. J. Drug Target. 11(3), 139-149 (2003).
29. Alexiou C, Schmid RJ, Jurgons R, et al. Targeting cancer cells: magnetic nanoparticles as drug carriers. Eur. Biophys. J. 35(5), 446-450 (2006).
30. Wiekhorst F, Seliger C, Jurgons R, et al. Quantification of magnetic nanoparticles by magnetorelaxometry and comparison to histology after magnetic drug targeting. J. Nanosci. Nanotechnol. 6(9-10), 3222-3225 (2006).
31. Alexiou C, Jurgons R, Seliger C, Brunke O, Iro H, Odenbach S. Delivery of superparamagnetic nanoparticles for local chemotherapy after intraarterial infusion and magnetic drug targeting. Anticancer Res. 27(4A), 2019-2022 (2007).
32. Richter H, Wiekhorst F, Schwarz K, et al. Magnetorelaxometric quantification of magnetic nanoparticles in an artery model after ex vivo magnetic drug targeting. Phys Med. Biol. 54(18), N417-N424 (2009).
33. Tietze R, Schreiber E, Lyer S, Alexiou C. Mitoxantrone loaded superparamagnetic nanoparticles for drug targeting: A versatile and sensitive method for quantification of drug enrichment in rabbit tissues using HPLC-UV. J. Biomed. Biotechnol. 597304 (2010).
34. Lyer S, Tietze R, Jurgons R, et al. Visualisation of tumour regression after local chemotherapy with magnetic nanoparticles -a pilot study. Anticancer Res. 30(5), 1553-1557 (2010).
35. Tietze R, Rahn H, Lyer S, et al. Visualization of superparamagnetic nanoparticles in vascular tissue using XμCT and histology. Histochem. Cell Biol. 135(2), 153-158 (2011).
36. El-Sayed IH. Nanotechnology in head and neck cancer: the race is on. Curr. Oncol. Rep. 12(2), 121-128 (2010).
37. Chen PY, Liu HL, Hua MY, et al. Novel magnetic/ultrasound focusing system enhances nanoparticle drug delivery for glioma treatment. Neuro. Oncol. 12(10), 1050-1060 (2010).
38. Hua MY, Liu HL, Yang HW, et al. The effectiveness of a magnetic nanoparticle-based delivery system for BCNU in the treatment of gliomas. Biomaterials 32(2), 516-527 (2011).
39. Lian G, Lewelling K, Johnson M, Dormer K, Gibson D, Seeney C. Silica-coated superparamagnetic Fe3O4 nanoparticles for biomedical applications. Microsc. Microanal. 10(Suppl. 2), 536-537 (2004).
40. Klostergaard J, Bankson J, Auzenne E, Gibson D, Yuill W, Seeney C. Magnetic vectoring of magnetically-responsive nanoparticles within the murine peritoneum. J. Magn. Magn. Mater. 311(1), 330-335 (2007).
41. Klostergaard J, Bankson J, Woodward W, Gibson D, Seeney C. Magnetically-responsive nanoparticles for vectored delivery of cancer therapeutics. AIP Conf. Proc. 1311(1), 382-387 (2011).
42. Schenck JF. The role of magnetic susceptibility in magnetic resonance imaging: MRI magnetic compatibility of the first and second kinds. Med. Phys. 23(6), 815-850 (1996).
43. Mallinson JC. One-sided fluxes -a magnetic curiosity? IEEE Trans. Magn. 9, 678-682 (1973).
44. Halbach K, Design of permanent multipole magnets with oriented rare earth cobalt material. Nucl. Instrum. Meth. 169, 1-10 (1980).
45. Kumada M, Antokhin EI, Iwashita Y, Aoki M, Sugiyama E. Super strong permanent dipole magnet. IEEE Trans. Appl. Supercond. 14(2), 1287-1289 (2004).
46. Lee MG, Lee SQ, Gweon D-G. Analysis of Halbach magnet array and its application to linear motor. Mechatronics 14(1), 115-128 (2004).
47. Pusenjak J, Miklavcic D. Modeling of interstitial fluid pressure in solid tumor. Sim. Pract. Theory 8, 17-24 (2000).
48. Salnikov AV, Iversen VV, Koisti M, et al. Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy. FASEB J. 17(12), 1756-1758 (2003).
49. Flessner MF, Choi J, Credit K, Deverkadra R, Henderson K. Resistance of tumor interstitial pressure to the penetration of intraperitoneally delivered antibodies into metastatic ovarian tumors. Clin. Cancer Res. 11, 3117-3125 (2005).
50. Fukumura D, Jain RK. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J. Cell. Biochem. 101(4), 937-949 (2007).
51. Medarova Z, Kumar M, Ng SW, Moore A. Development and application of a dual-purpose nanoparticle platform for delivery and imaging of siRNA in tumors. Methods Mol. Biol. 555, 1-13 (2009).
52. del Pino P, Munoz-Javier A, Vlaskou D, Rivera Gil P, Plank C, Parak WJ. Gene silencing mediated by magnetic lipospheres tagged with small interfering RNA. Nano Lett. 10(10), 3914-3921 (2010).
53. Veiseh O, Kievit FM, Fang C, et al. Chlorotoxin bound magnetic nanovector tailored for cancer cell targeting, imaging, and siRNA delivery. Biomaterials 31(31), 8032-8042 (2010).
54. Hill JM, Dick AJ, Raman VK, et al. Serial cardiac magnetic resonance imaging of injected mesenchymal stem cells circulation. 108, 1009-1014 (2003).
55. Budde MD, Frank JA. Magnetic tagging of therapeutic cells for MRI. J. Nucl. Med. 50(2), 171-174 (2009).
56. Kim YS, Park IK, Kim WJ, et al. SPION nanoparticles as an efficient probe and carrier of DNA to umbilical cord blood-derived mesenchymal stem cells. J. Nanosci. Nanotech. 11(2), 1507-1510 (2011).
57. Makhmudov SY, Kuznetsov AA, Filippov VI. Scientific and Clinical Applications of Magnetic Carriers. Hafeli U, Schutt W, Teller J, et al. (Eds). Plenum Press, NY, USA, 495 (1997).
58. Kubo T, Sugita T, Shimose S, Nitta Y, Ikuta Y, Murakami T. Targeted delivery of anticancer drugs with intravenously administered magnetic liposomes in osteosarcoma-bearing hamsters. Int. J. Oncol. 17(2), 309-315 (2000).
59. Hafeli UO. Magnetically modulated therapeutic systems Int. J. Pharm. 277 19-24 (2004).
60. Iacob G, Rotariu O, Strachan NJC, Häfeli UO. Magnetizable needles and wires -modeling an efficient way to target magnetic microspheres in vivo. Biorheology 41, 599-612 (2004).
61. Chen HT, Ebner AD, Rosengart AJ, Kaminski MD, Ritter JA. Analysis of magnetic drug carrier particle capture by a magnetizable intravascular stent: 1. Parametric study with single wire correlation. J. Magn. Magn. Mater. 284, 181-194 (2004).
62. Yellen BB, Forbes ZG, Halverson DS, et al. Targeted drug delivery to magnetic implants for therapeutic applications. J. Magn. Magn. Mater. 293, 647 (2005).